Dawn Vanderhoef, PhD, DNP

Associate Medical Director, Medical Affairs, Psychiatry
Neurocrine Biosciences, Inc.

Poster(s):

• (347) Estimation of the minimal clinically important difference (MCID) and longitudinal change in the tardive dyskinesia impact scale (TDIS), a validated, tardive dyskinesia-specific, patient-reported outcome measure
  Wednesday, October 29, 2025

• (363) Real-world insights on tardive dyskinesia: a claims-based analysis of demographics and healthcare utilization
  Wednesday, October 29, 2025